



**COMPANY ANNOUNCEMENT  
31 August 2010**

Centralised Company Announcements Platform  
Australian Stock Exchange  
10th floor, 20 Bond Street  
Sydney NSW 2000

**ENTITLEMENT ISSUE**

**Cleansing Notice under section 708AA(2)(f) of the Corporations Act**

This notice is given by NeuroDiscovery Limited under section 708AA(2)(f) of the Corporations Act 2001 (the "Act") as notionally modified by ASIC Class Order 08/35.

NeuroDiscovery has announced on 30 August 2010 a non-renounceable entitlement offer ("Entitlement Offer") of 1 fully paid NeuroDiscovery ordinary share ("New Shares") for every 2 NeuroDiscovery ordinary shares held as at 4:00 pm (AEDT) on 9 September 2010 by eligible shareholders.

NeuroDiscovery advises that:

- (a) the New Shares will be offered for issue without disclosure under Part 6D.2 of the Act;
- (b) the notice is being given under section 708AA(2)(f) of the Act;
- (c) as at the date of this notice, NeuroDiscovery has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to NeuroDiscovery; and
  - (ii) section 674 of the Act;
- (d) as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Act; and
- (e) the potential effect the Entitlement Offer may have on the control of NeuroDiscovery, and the consequences of that effect, will depend on a number of factors, including investor demand and the likely spread of sub underwriting arrangements. The Underwriter may acquire a voting power in the Company's shares of up to a maximum of 33% as a result of subscribing for any Shortfall Securities under the Offer. However the Underwriter has advised the Company that it has entered into (or will enter into) general sub-underwriting agreements for the Shortfall Securities, such that neither the Underwriter nor any of its sub-underwriters, individually, will have a voting power in the Company in excess of 20%.

**Yours faithfully**

Harry Karelis – Non Executive Chairman
T: +61 413 056 328
E: hkarelis@titanbioventures.com

**-ENDS-**

**About NeuroDiscovery**

NeuroDiscovery Ltd is an ASX listed speciality neuroscience drug development company (ASX Code NDNL).